Dissecting the genomic traits and clinical course of secondary myelodysplastic syndrome following aplastic anaemia: A milestone

Carmelo Gurnari; Valeria Visconte

doi:10.1111/bjh.19898

Dissecting the genomic traits and clinical course of secondary myelodysplastic syndrome following aplastic anaemia: A milestone

Br J Haematol. 2024 Nov 14. doi: 10.1111/bjh.19898. Online ahead of print.

Authors

Carmelo Gurnari^{1

2}, Valeria Visconte¹

Affiliations

¹ Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
² Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy.

PMID: 39542742
DOI: 10.1111/bjh.19898

Abstract

Dissecting the genomic traits and clinical course of secondary myelodysplastic syndrome following aplastic anaemia is a milestone. The report by Li and colleagues investigates determinants of evolution to myelodysplastic syndrome and acute myeloid leukaemia in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria with a specific focus on post-transplant outcomes. Commentary on: Li et al. Clinical and genetic profiles and outcomes of allogeneic haematopoietic stem cell transplantation in secondary myelodysplastic syndrome following aplastic anaemia. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19855.

Keywords: aplastic anemia; genomic traits; secondary myelodysplastic syndrome.